Phase 1 Study of Safety and Immunogenicity of Ad4-H5-VTN in Ad4 Seronegative Volunteers.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; Influenza A virus vaccine-H5N1 (Primary) ; Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- 01 Mar 2021 Results published in the Journal of Clinical Investigation.
- 25 Apr 2018 Status changed from recruiting to completed.
- 14 Mar 2012 Additional lead trial investigator (Mark Connors) identified as reported by ClinicalTrials.gov.